US FDA puts clinical hold on Neumora Therapeutics' brain disease study due to convulsions in rabbits.
Neumora Therapeutics' shares fell after the US FDA put a clinical hold on an early-stage study of its brain disease treatment following safety findings of convulsions in rabbits. The study involved about 30 patients who received doses of the drug NMRA-266, with no convulsions observed in any participant. The company is working with the FDA to resolve the clinical hold and will provide updates when available.
April 15, 2024
14 Articles